Trials / Completed
CompletedNCT02430714
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 629 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 24mg once daily oral dosing to Unresectable thyroid cancer patients |
Timeline
- Start date
- 2015-05-20
- Primary completion
- 2016-11-06
- Completion
- 2016-11-06
- First posted
- 2015-04-30
- Last updated
- 2020-01-09
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02430714. Inclusion in this directory is not an endorsement.